[12] Monitoring and patient safety advice: Patients should be monitored regularly during treatment, with assessment of: Weight and BMI Metabolic parameters (fasting glucose, HbA1c, lipid profile) Menstrual cycle patterns Symptoms of adverse effects When to contact your GP: Patients should seek medical advice if they experience severe or persistent abdominal pain, signs of pancreatitis, symptoms of gallbladder disease, unexplained neck lumps, significant mood changes, or if they suspect pregnancy
Semaglutide, also injected weekly, lowered body weight by about 11% after 24 to 68 weeks , with evidence suggesting sustained effects up to two years, based on 18 randomized controlled trials involving 27,949 participants
Die Aktivierung des GLP-1-Rezeptors resultiert in einer Stimulation der Adenylylcyclase (AC), die ATP in cAMP umwandelt
It has shown a strong safety profile in animal research and good tolerance in human research subjects, but large-scale human clinical trials are still needed